Chinese investors face cultural barriers in acquiring foreign assets

14 May 2018

By Wang Fangqing

As more Chinese pharma companies are seeking potential assets globally, especially biotech startups, they need to be aware of cultural differences, which in some cases could even blow up a deal, noted speaks at ChinaBio partnering forum held in Suzhou on Apr 26, reports The Pharma Letter’s local correspondent Wang Fangqing.

For example, it is accepted in China that a buyer and a target talk about a possible acquisition at their first meeting, but such a practice is unusual in Europe, said Erik Digman Wiklund, chief financial officer at TargoVax, a Norwegian biotech for immunotherapies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK